USANA Health Sciences (NYSE: USNA) reported Q1 EPS of $0.91, $0.01 worse than the analyst estimate of $0.92. Revenue for the quarter came in at $255.3 million versus the consensus estimate of $253.51 million.

GUIDANCE:

USANA Health Sciences sees FY2017 EPS of $3.80-$4.10, versus the consensus of $4.10. USANA Health Sciences sees FY2017 revenue of $1.04-1.07 billion, versus the consensus of $1.06 billion.

“USANA generated solid top-line and customer growth during the quarter,” said Kevin Guest, Chief Executive Officer. “Our earnings were impacted by additional expense related to our previously disclosed internal investigation during the quarter. Setting aside these expenses, our bottom-line results were essentially in-line with our expectations. We remain focused on implementing our 2017 growth strategies, including our initiatives designed to drive overall customer growth and our new product announcements later this year.”

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.